CMAJ. 1996 Oct 15;155(8):1113-33.
To recommend clinical practice guidelines for the assessment of people at risk for osteoporosis, and for effective diagnosis and management of the condition.
Screening and diagnostic methods: risk-factor assessment, clinical evaluation, measurement of bone mineral density, laboratory investigations. Prophylactic and corrective therapies: calcium and vitamin D nutritional supplementation, physical activity and fall-avoidance techniques, ovarian hormone therapy, bisphosphonate drugs, other drug therapies. Pain-management medications and techniques.
Prevention of loss of bone mineral density and fracture; increased bone mass; and improved quality of life.
Epidemiologic and clinical studies and reports were examined, with emphasis on recent randomized controlled trials. Clinical practice in Canada and elsewhere was surveyed. Availability of treatment products and diagnostic equipment in Canada was considered.
Cost-effective methods and products that can be adopted across Canada were considered. A high value was given to accurate assessment of fracture risk and osteoporosis, and to increasing bone mineral density, reducing fractures and fracture risk and minimizing side effects of diagnosis and treatment.
BENEFITS, HARMS AND COSTS: Proper diagnosis and management of osteoporosis minimize injury and disability, improve quality of life for patients and reduce costs to society. Rationally targeted methods of screening and diagnosis are safe and cost effective. Harmful side effects and costs of recommended therapies are minimal compared with the harms and costs of untreated osteoporosis. Alternative therapies provide a range of choices for physicians and patients.
Population sets at high risk should be identified and then the diagnosis confirmed through bone densitometry. Dual-energy x-ray absorptiometry is the preferred measurement technique. Radiography can be adjunct when indicated. Calcium and vitamin D nutritional supplementation should be at currently recommended levels. Patients should be counselled in fall-avoidance techniques and exercises. Immobilization should be avoided. Guidelines for management of acute pain are listed. Ovarian hormone therapy is the therapy of choice for osteoporosis prevention and treatment in postmenopausal women. Bisphosphonates are an alternative therapy for women with established osteoporosis who cannot or prefer not to take ovarian hormone therapy.
推荐用于评估骨质疏松症风险人群以及对该病症进行有效诊断和管理的临床实践指南。
筛查和诊断方法:风险因素评估、临床评估、骨密度测量、实验室检查。预防和矫正疗法:钙和维生素D营养补充、体育活动和预防跌倒技术、卵巢激素疗法、双膦酸盐药物、其他药物疗法。疼痛管理药物和技术。
预防骨密度丢失和骨折;增加骨量;改善生活质量。
审查了流行病学和临床研究及报告,重点是近期的随机对照试验。调查了加拿大及其他地区的临床实践。考虑了加拿大治疗产品和诊断设备的可用性。
考虑了可在加拿大各地采用的具有成本效益的方法和产品。高度重视准确评估骨折风险和骨质疏松症,以及增加骨密度、降低骨折和骨折风险并尽量减少诊断和治疗的副作用。
益处、危害和成本:对骨质疏松症进行正确的诊断和管理可将损伤和残疾降至最低,改善患者生活质量并降低社会成本。合理靶向的筛查和诊断方法安全且具有成本效益。与未治疗的骨质疏松症的危害和成本相比,推荐疗法的有害副作用和成本最小。替代疗法为医生和患者提供了一系列选择。
应识别高危人群,然后通过骨密度测定法确诊。双能X线吸收法是首选的测量技术。如有指征,放射照相可作为辅助手段。钙和维生素D营养补充应达到当前推荐水平。应向患者提供预防跌倒技术和锻炼方面的咨询。应避免固定不动。列出了急性疼痛管理指南。卵巢激素疗法是绝经后妇女预防和治疗骨质疏松症的首选疗法。双膦酸盐是已确诊骨质疏松症且不能或不愿接受卵巢激素疗法的女性的替代疗法。